secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGENUS INC (AGEN)
CIK:        0001098972
Form:       8-K
Filed at:   2026-03-16T23:59:59+00:00
Accession:  0001193125-26-107288
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agenus reports $4.2M initial BOT+BAL revenue; net loss narrows to $3.1M in FY2025
--------------------------------------------------------------------------------

- Pre-commercial product revenue of $4.2M from early access programs in France and paid NPP across 30+ countries.
- BOT+BAL shows 42% two-year OS and ~21-month median OS in heavily pretreated MSS mCRC; Phase 3 BATTMAN trial initiated.
- France AAC expanded to ovarian cancer and sarcoma in January 2026; 200+ physician inquiries received globally.
- Zydus collaboration provided $91M upfront capital; $20M contingent payment triggered in March 2026 for manufacturing.
- Q4 2025 operating income $14.4M; full year net loss $3.1M vs prior year; other revenue $110M (non-cash royalty).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1098972/000119312526107288/0001193125-26-107288-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1098972/000119312526107288/agen-20260316.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-107288

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer